Back to top

Alnylam Pharmaceuticals, Inc. (ALNY)

(Delayed Data from NSDQ)

$132.41 USD


+3.78 (2.94%)

Updated May 11, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
5Strong Sell3.06%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (221 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Cambridge, MA-based Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas (STArs) – genetic medicines, cardio-metabolic disease and hepatic infectious disease.

In August 2018, the company’s lead drug-Onpattro (patisiran) received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved treatment for this indication. In November 2019, the FDA approved Givlaari (givosiran) ...

General Information

Alnylam Pharmaceuticals, Inc.



Phone: 617-551-8200

Fax: 617-551-8101



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date 8/5/2021

EPS Information

Current Quarter EPS Consensus Estimate -1.56
Current Year EPS Consensus Estimate -6.19
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 8/5/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 128.63
52 Week High 178.41
52 Week Low 119.29
Beta 1.25
20 Day Moving Average 509,456.56
Target Price Consensus 175.68


% Price Change
4 Week -4.74
12 Week -18.55
YTD -1.03
% Price Change Relative to S&P 500
4 Week -6.11
12 Week -23.48
YTD -11.25
Share Information
Shares Outstanding (millions) 117.54
Market Capitalization (millions) 15,119.82
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -5.56%
vs. Previous Quarter 18.18%
Sales Growth
vs. Previous Year 78.50%
vs. Previous Quarter 8.56%
Price Ratios
Price/Book 16.33
Price/Cash Flow NA
Price / Sales 26.48
3/31/21 -76.92
12/31/20 -68.93
9/30/20 -65.96
3/31/21 -26.27
12/31/20 -27.76
9/30/20 -31.38
Current Ratio
3/31/21 4.99
12/31/20 4.47
9/30/20 5.32
Quick Ratio
3/31/21 4.84
12/31/20 4.34
9/30/20 5.18
Operating Margin
3/31/21 -153.49
12/31/20 -174.15
9/30/20 -222.19
Net Margin
3/31/21 -153.49
12/31/20 -174.15
9/30/20 -222.19
Pre-Tax Margin
3/31/21 -152.95
12/31/20 -173.60
9/30/20 -221.61
Book Value
3/31/21 7.88
12/31/20 8.75
9/30/20 10.46
Inventory Turnover
3/31/21 1.31
12/31/20 1.08
9/30/20 1.00
3/31/21 0.21
12/31/20 0.19
9/30/20 0.00
Debt to Capital
3/31/21 17.14
12/31/20 15.84
9/30/20 0.00